Latest news with #IDT
Forbes
2 days ago
- Business
- Forbes
Collaboration Is Key To The Future Of Cancer Research And Innovation
Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial. Advances in next generation sequencing (NGS) technologies have enabled cancer research innovations like improvements in minimal residual disease (MRD) identification and the discovery of drugs that target genetic tumor abnormalities. These approaches were backed by collaborations between developers and genomic technology suppliers who combined their scientific expertise and manufacturing capabilities to accelerate the pace of cancer research for the patients they serve. When forming these alliances, cancer researchers are faced with a growing selection of NGS providers, some of which pitch what they consider to be disruptive solutions. These alternative solutions can, at times, focus more on speed and cost—a concept suggesting that quicker insights will reduce the need for additional sequencing, equating to more tests performed and rapid breakthroughs to market. No doubt, speed and efficiency matter. But prioritizing 'fast and new' can be detrimental to driving cancer research innovation. In my opinion, a more effective approach is partnership: entering strategic relationships with genomic providers that have the quality, knowledge and capabilities to design optimized assays that generate reproducible results, making them your trusted partner from discovery through clinical development. How Researchers Are Leveraging Partnerships The key to obtaining better, more actionable insights from NGS assays is to create flexible yet optimized end-to-end workflows from library preparation to data analysis. These workflows are all customized to the experiment at hand and led by an NGS expert who has both strong in-house capabilities and a track record of collaborating with partners that help solve labs' biggest challenges. This is not just about forming one strong alliance with an innovative technology provider—it's also about benefiting from that partner's wider network of collaborators. To streamline research, developers can work hand in hand with technology providers to create or optimize customized panels, adapters, library prep and other reagents for the most robust assay to fit their needs. Among the many applications where it's vital to prioritize quality over speed in cancer research is the identification of MRD. Researchers use NGS to identify MRD by measuring circulating cell-free DNA (cfDNA) through the presence of low-frequency mutations that are known to be associated with the cancer type being studied. The MRD research and testing field is consistently growing as new genes of interest are found in blood cancers such as leukemia, lymphoma and myeloma. To support this research, developers are engaging with vendors to design new panels. Collaborations between the developers and their strategic partners also help establish high standards and metrics, so laboratories can maintain consistent data, resulting in the most reliable and confident insights possible. The most effective collaborations benefit from enhancing their capabilities by embracing outside expertise. For instance, my company, Integrated DNA Technologies (IDT), deploys continuous improvement strategies. We also have a strategic alliance with a Bio-IT company so customers can pair insights obtained from secondary analysis platforms with tertiary variant annotation and reporting software to contextualize data for both known and newly discovered variants. Recently, we also formed an innovation hub to foster innovative ideas and advancements, and foster customer collaboration. By combining expertise, manufacturing and technology capabilities, genomics providers can stay at the forefront of emerging technologies, strengthen their own capabilities to support customers, and enhance their market knowledge. Best Practices When Entering Partnerships With NGS Technology Providers Cancer researchers must collaborate with their NGS suppliers to foster a more business-minded approach to accelerating innovation. To accomplish this, developers must view their suppliers as strategic partners and work in unison to leverage their expertise, domain knowledge and supply chain management. This comprehensive approach is beneficial for researchers: It ensures a supplier's capabilities closely align with their lab's scientific objectives, resulting in increased productivity, lower inventory costs and overall savings. View them as more than a transactional arrangement so that each party can appreciate the value of partnership to advance the industry and overcome hurdles with technology sharing, regulatory roadblocks and overall cost burden. As the partnership matures, there will be an upside, such as realizing the economic and business benefits that working together brings. When evaluating expertise, experience matters. Third-party validation, proof-of-concept, comparative testing and a diverse customer base are a few ways to assess an NGS supplier's track record. These factors help distinguish a partner that can provide quality, expertise and consistency over a vendor that displays disruptive new technology. While not all partnerships will be a good fit, in order for them to succeed, it must be a win-win and provide a synergistic benefit that fills an industry, market or technology gap, solves a customer problem, or accelerates therapeutic development. Conclusion Strategic partnerships between developers and suppliers will continue to drive important innovations in NGS for cancer research. But to truly drive maximum benefit from these partnerships, developers who want to maximize insights should prioritize expertise and quality of data over disruptive new technology focused solely on speed and cost. For cancer patients awaiting new therapies, the stakes are too high. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Yahoo
24-06-2025
- Business
- Yahoo
IDT Corporation (IDT): A Bull Case Theory
We came across a bullish thesis on IDT Corporation on Polymath Investor substack by Polymath Investor. In this article, we will summarize the bulls' thesis on IDT. IDT Corporation's share was trading at $66.08 as of 18th June. IDT's trailing and forward P/E was 17.4 according to Yahoo Finance. People using the Cash App paying for goods and services, highlighting the impact the of the company's payment tools. IDT Corporation is quietly undergoing a significant transformation, evolving from a legacy telecom operator into a high-growth fintech and B2B services platform. At the heart of this shift are its two standout segments: National Retail Solutions (NRS) and BOSS Money. These businesses are driving explosive year-over-year growth, significantly boosting the company's overall profitability. Last quarter, gross margins reached a record 37.1%, with fintech gross profit rising 31%, underscoring the momentum behind IDT's earnings surge—GAAP EPS jumped to $0.86 in Q3 FY25 from just $0.22 a year prior. While the company's total revenue appears flat, this masks the rapid expansion of its fintech operations and the relative decline of its traditional telecom business, which is increasingly fading into the background. There is a growing belief that these high-growth fintech segments could unlock considerable shareholder value if separated, given their potential to command significantly higher valuation multiples on a standalone basis. Management's history of successful spin-offs adds credibility to this possibility, suggesting a strategic separation or sale of the fintech assets could be on the horizon. However, key risks remain, including whether telecom revenue erosion will outpace digital growth and whether management will ultimately follow through with a spin or monetization strategy. Despite these uncertainties, the underlying growth in NRS, BOSS Money, and a third emerging segment points to a compelling story that is still largely underappreciated by the market. For investors seeking asymmetric upside, IDT's pivot offers multiple potential catalysts for a rerating, and the stock merits a closer look. Previously we covered a bullish thesis on IDT Corporation by LittleBarnSparrow in January 2025, which highlighted the company's strong operational performance, high-growth segments like NRS and BOSS Money, and a solid balance sheet supporting strategic reinvestments. The company's stock price has appreciated approximately 41% since our coverage. This is because the fintech segments continued their rapid expansion, driving earnings growth. The thesis still stands as IDT's growth runway in NRS and BOSS Money remains intact, with rising margins and market penetration. Polymath Investor shares a similar view but emphasizes a potential spin-off or sale of the fintech segments as a key rerating catalyst. IDT Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held IDT at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the risk and potential of IDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
IDT Corporation (IDT): A Bull Case Theory
We came across a bullish thesis on IDT Corporation on Polymath Investor substack by Polymath Investor. In this article, we will summarize the bulls' thesis on IDT. IDT Corporation's share was trading at $66.08 as of 18th June. IDT's trailing and forward P/E was 17.4 according to Yahoo Finance. People using the Cash App paying for goods and services, highlighting the impact the of the company's payment tools. IDT Corporation is quietly undergoing a significant transformation, evolving from a legacy telecom operator into a high-growth fintech and B2B services platform. At the heart of this shift are its two standout segments: National Retail Solutions (NRS) and BOSS Money. These businesses are driving explosive year-over-year growth, significantly boosting the company's overall profitability. Last quarter, gross margins reached a record 37.1%, with fintech gross profit rising 31%, underscoring the momentum behind IDT's earnings surge—GAAP EPS jumped to $0.86 in Q3 FY25 from just $0.22 a year prior. While the company's total revenue appears flat, this masks the rapid expansion of its fintech operations and the relative decline of its traditional telecom business, which is increasingly fading into the background. There is a growing belief that these high-growth fintech segments could unlock considerable shareholder value if separated, given their potential to command significantly higher valuation multiples on a standalone basis. Management's history of successful spin-offs adds credibility to this possibility, suggesting a strategic separation or sale of the fintech assets could be on the horizon. However, key risks remain, including whether telecom revenue erosion will outpace digital growth and whether management will ultimately follow through with a spin or monetization strategy. Despite these uncertainties, the underlying growth in NRS, BOSS Money, and a third emerging segment points to a compelling story that is still largely underappreciated by the market. For investors seeking asymmetric upside, IDT's pivot offers multiple potential catalysts for a rerating, and the stock merits a closer look. Previously we covered a bullish thesis on IDT Corporation by LittleBarnSparrow in January 2025, which highlighted the company's strong operational performance, high-growth segments like NRS and BOSS Money, and a solid balance sheet supporting strategic reinvestments. The company's stock price has appreciated approximately 41% since our coverage. This is because the fintech segments continued their rapid expansion, driving earnings growth. The thesis still stands as IDT's growth runway in NRS and BOSS Money remains intact, with rising margins and market penetration. Polymath Investor shares a similar view but emphasizes a potential spin-off or sale of the fintech segments as a key rerating catalyst. IDT Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held IDT at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the risk and potential of IDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Record
23-06-2025
- Sport
- Daily Record
Renfrewshire community sports projects receive £2m funding boost
Renfrewshire Council has confirmed an allocation of £780,000 from its artificial pitches grant fund. Two major community sports projects in Renfrewshire have hit the back of the net with a £2 million investment. Renfrewshire Council has confirmed an allocation of £780,000 from its artificial pitches grant fund which will be more than match-funded by the Scottish Football Association's (SFA) Scottish Football facilities fund. The cash will support the development of new artificial playing surfaces for Thorn Athletic Community Trust and Inchinnan Development Trust (IDT), with each organisation receiving £390,000 from the council. There will also be £432,194 for Thorn and £667,906 for IDT from the SFA. The funding will help deliver high-quality, multi-sport facilities that will be fully inclusive and accessible to the local community. A third project at Renfrew FC to upgrade and replace their current surface will be supported by £196,601 from the SFA and brings the total investment in Renfrewshire's artificial pitch provision to more than £2m. The news is a huge boost to Johnstone-based Thorn who suffered last month when thousands of pounds worth of equipment was set alight in a shipping container at their Greenend Avenue base. Alongside their extensive football programme, Thorn also demonstrated the provision of multi-sport activity and strong partnerships with other local community groups. And the fresh surface will help meet the requirement for new artificial pitches in the area identified in the council's pitches strategy. Mark McGee, chairperson of Thorn Athletic community Trust, said: 'Everyone at Thorn Athletic is overjoyed with this funding award and we realise the significance of it for everyone in the community. 'We look forward to developing our facilities, expanding what we can offer and increasing the social impact of our work. This will allow us to secure our footprint at the heart of Johnstone for decades to come.' IDT will focus on Under-18s football through its relationship with St Mirren Youth Football Club while supporting other sports, including a partnership with Bishopton Rugby Club. Maggie Morrison, operations and development manager at IDT, said: 'To say we are thrilled by this funding success would be an understatement. We are ecstatic and filled with excitement, with a healthy dose of nervous energy, too. 'Our first application to the SFA was not robust enough so I'm delighted that, after using the feedback to build a stronger foundation and harnessing the dedication of trust staff, volunteers and board members, we have been successful the second time around. 'We recognise it is vitally important we bring the entire community with us on this journey, delivering improved facilities while showing respect and consideration to our neighbours. 'We can't wait to begin delivering for the people of Renfrewshire one of the first fully recyclable, organically infilled artificial pitches in the West of Scotland. The future is looking green, sustainable, and incredibly bright.' The grant fund was launched following a Renfrewshire Council budget commitment of £800,000 to improve outdoor sports provision across the area. It was designed to support community-led organisations in delivering new artificial pitches – with a focus on sustainability, community benefit, and increasing participation in sport. Applications were assessed against a robust set of criteria including community impact, project readiness, sustainability and alignment with local authority priorities. Council officers will continue to work with Johnstone Burgh Community Club and Calderglen Community SCIO whose applications were not successful in exploring alternative funding opportunities and supporting them in developing their proposals further. Councillor Andy Steel, who represents Johnston South and Elderslie, says that, although it was 'disappointing' to learn Burgh's application was rejected, seeing Thorn Athletic, IDT and Renfrew be successful was a positive. Renfrewshire but, of course, I'm most pleased to see funding going into Johnstone. 'Thorn Athletic's bid met all the criteria and, especially after recent events, the funding will, I hope, be very welcome. 'I was disappointed the Burgh application was declined after scoring 89 per cent in the assessment – I'd settle for 89 per cent in a test anytime. 'However, council officers have told me that they will remain in contact with Burgh and ensure they receive support to apply if and when future funding is available.'
Business Wire
16-06-2025
- Health
- Business Wire
Integrated DNA Technologies Announces Innovation Roadmap Advances to Infectious Disease Portfolio
CORALVILLE, Iowa--(BUSINESS WIRE)-- Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research efforts in monitoring infectious disease dynamics, supporting surveillance and accelerating biomarker discovery. As part of its innovation roadmap, focused on enabling academic and medical researchers, health organizations, and the scientific community prepare for ongoing and future global health challenges, IDT has unveiled two new powerful tools: The PrimeTime™ Influenza Kit and PrimeTime Research Pathogen Panels. These differentiated offerings expand upon IDT's current infectious disease portfolio of qPCR and next generation sequencing (NGS) solutions comprised of stand-alone library preparation, target enrichment and normalization chemistries, as well as connected DNA solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms, drug development research and more. 'Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges,' said Adler Edward. Share First to Market: Complete Solution for Influenza Research Launching at ASM Microbe 2025 is IDT's PrimeTime Influenza Kit, the first complete qPCR solution of its kind designed specifically to amplify common influenza strains. The kit targets Influenza A, Influenza A (H5N1), Influenza B, and RNase. It includes an internal control for sample quality assessment, a pre-mixed primer and probe set, PrimeTime 4x Broad-Range Master Mix and direct amplification enhancer. This streamlined solution enables researchers to generate high-confidence data for both seasonal and emerging influenza strains. New Cost-effective Solution to Accelerate Sexual Health and Pathogen Research IDT is also showcasing its new PrimeTime Research Pathogen Panels, a customizable, high-throughput solution that allows researchers to identify key sequences and mutations across 10 diverse research applications—spanning respiratory, gastrointestinal and sexual health studies—and an 11th category for viral infection research. The mix-and-match format across targets and dyes enables scientists to select from a broad list of targets to maximize cost and time savings. The panels' flexible assay configuration facilitates rapid, multiplexed detection and characterization of pathogens, with up to 211 available targets including sexually transmitted infections, human papillomavirus, urinary tract infections and more. With seamless integration into existing qPCR workflows, this single-tube offering equips researchers with innovative tools for exploring pathogen dynamics across individual and population-level studies. 'Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges,' said Adler Edward, VP, Gene Reading Components at IDT. 'By delivering robust, customizable and high-quality solutions, backed by IDT's trusted technical and scientific expertise, researchers can feel confident in accelerating their discoveries and deepening their understanding of pathogen dynamics in human health.' To learn more about IDT's infectious disease innovation roadmap and how these new offerings are shaping the future of virus transmission research, visit IDT at ASM Microbe 2025 at booth #1723. To place an order, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
